Below are our currently enrolling studies for patients with gout.
Sponsor: Olatec Therapeutics LLC
Protocol Number: OLT1177-08
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Detailed Information:
To learn more or see if you qualify: Click Here
Sponsor: Amgen
Protocol Number: 20230219
The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus pegloticase 8 mg intravenously (IV) every two weeks with MTX on the response rate during Month 6, as measured by the sustained normalization of serum uric acid (sUA) to < 6 mg/dL for at least 80% of the time during Month 6.
Detailed Information:
To learn more or see if you qualify: Click Here